Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Radiotherapy in Gynecological Cancer: State of the Art
share announcement

Radiotherapy in Gynecological Cancer: State of the Art

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1349

Special Issue Editors

Dr. Àngeles Rovirosa

E-Mail Website
Guest Editor
Fonaments Clinics Department, Faculty of Medicine, Universitat de Barcelon, Barcelona, Spain
Interests: interventional radiotherapy; brachytherapy techniques; gynecological oncology; educational gynecology
Special Issues, Collections and Topics in MDPI journals
Dr. Gabriella Macchia

E-Mail Website
Guest Editor
Radiation Oncology Unit, Gemelli Molise Hospital, Campobasso, Italy
Interests: radiation oncology; gynecological, breast and gastrointestinal tract neoplasms
Dr. Luca Tagliaferri

E-Mail Website
Guest Editor
Gemelli ART (Advanced Radiation Therapy)-Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Interests: interventional radiotherapy (brachytherapy); metabolic radiotherapy; medical software development; eye cancer; vulvar cancer; skin cancer; head and neck cancer; prostate cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue of Cancers considers the quick evolution of radiation oncology in the gynaecological tumour sites of endometrial, cervical, vaginal and vulvar cancers. Considering the variety of advances achieved in the last decade, radiotherapy in gynaecological cancer has become increasingly well established and there has been an increase in cancer treatment results. At present, new indications and new techniques to be employed in this scenario include intensity-modulated radiotherapy, image-guided external beam irradiation, image-guided brachytherapy, stereotactic body radiation and intraoperative radiotherapy between others. Recently, tumour markers have been related to radiotherapy indications, leading omics-based and other adjuvant treatments to now be in the pipeline. Artificial intelligence is currently being developed for future use in this field.

This is a promising Special Issue that aims to establish the state of the art in the radiotherapy of gynaecological cancers via reviews or research articles developed by radiation oncologists, medical oncologists and medical physicists, with a view into the future.

The Guest Editors of this Special Issue look forward to receiving your contributions.

Dr. Àngeles Rovirosa
Dr. Gabriella Macchia
Dr. Luca Tagliaferri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • interventional radiotherapy
  • brachytherapy techniques
  • gynecological oncology
  • educational gynecology
  • gynecological cancer

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 2676 KiB  
Article
Stages I–III Inoperable Endometrial Carcinoma: A Retrospective Analysis by the Gynaecological Cancer GEC-ESTRO Working Group of Patients Treated with External Beam Irradiation and 3D-Image Guided Brachytherapy
by Ángeles Rovirosa, Yaowen Zhang, Kari Tanderup, Carlos Ascaso, Cyrus Chargari, Elzbieta Van der Steen-Banasik, Piotr Wojcieszek, Magdalena Stankiewicz, Dina Najjari-Jamal, Peter Hoskin, Kathy Han, Barbara Segedin, Richard Potter and Erik Van Limbergen
Cancers 2023, 15(19), 4750; https://doi.org/10.3390/cancers15194750 - 27 Sep 2023
Viewed by 1062
Abstract
Background/Purpose: Analyse the outcomes of stages I–III inoperable endometrial cancer (IEC) patients treated with external-beam-irradiation (EBRT) and 3D-image-guided-brachytherapy (IGBT). Material and Methods: Medical records of IEC patients receiving EBRT + IGBT in eight European and one Canadian centres (2004–2019) were examined, including: pelvic [...] Read more.
Background/Purpose: Analyse the outcomes of stages I–III inoperable endometrial cancer (IEC) patients treated with external-beam-irradiation (EBRT) and 3D-image-guided-brachytherapy (IGBT). Material and Methods: Medical records of IEC patients receiving EBRT + IGBT in eight European and one Canadian centres (2004–2019) were examined, including: pelvic ± para-aortic EBRT and lymph node boost; anaesthetic procedure, applicators, BT-planning imaging, clinical target volume (CTV), brachytherapy schedule, and EQD2 to the CTV(α/β=4.5Gy) and D2 cm3(α/β=3Gy) for organs at risk. Complications are evaluated using CTCAEv4 scores. The 2- and 5-year survival probability according to stages was estimated (cancer-specific survival (CSS), disease-free survival (DFS), local relapse-free survival (LRFS), loco-regional relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS)). Statistics: descriptive analysis and the Kaplan–Meier method. Results: 103 patients (stages: I-44, II-14, III-44) were included. Median follow-up: 28 months (7–170). All patients received pelvic ± para-aortic EBRT. Median D90-EQD2(α/β=4.5) to the CTV:73.3 Gy (44.6–132.7), 69.9 Gy (44.7–87.9 and 75.2 Gy (55.1–97) in stages I, II, and III, respectively. Thirty patients presented relapse (stages: 10-I, 3-II, 17-III): 24 uterine (stages: 7-I, 3-II, 14-III), 15 nodal (stages: 4-I, 1-II, 10-III), and 23 distant (stages: 6-I, 2-II, 15-III). Five year CSS was 71.2% (stages: 82%-I-II and 56%-III) and DFS, LRFS, LRRFS, and DMFS were 55.5%, 59%, 72%, and 67.2%, respectively. Late G3-G4 complications (crude): 1.3% small bowel, 2.5% rectum, and 5% bladder. Conclusion: In stages I–III of the IEC, EBRT + IGBT offer good 2- and 5-year CSS of 88.7% and 71.2%, respectively, with the best outcomes in stages I–II. Prospective studies are needed to determine how better outcomes can be achieved. Full article
(This article belongs to the Special Issue Radiotherapy in Gynecological Cancer: State of the Art)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop